Compare · CINC vs NVO
CINC vs NVO
Side-by-side comparison of CinCor Pharma Inc. (CINC) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CINC and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 290.0x CINC ($661.4M).
- NVO has hit the wire 8 times in the past 4 weeks while CINC has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 9 for CINC).
- Company
- CinCor Pharma Inc.
- Novo Nordisk A/S
- Price
- $29.08-0.38%
- $41.65-3.02%
- Market cap
- $661.4M
- $191.82B
- 1M return
- -
- -9.04%
- 1Y return
- -
- -44.81%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 0
- 8
- Recent ratings
- 9
- 25
CinCor Pharma Inc.
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CINC
- Axonis Therapeutics Announces $115 Million Series A Financing
- venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies
- Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
- 5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science
- SEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)
- SEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)
- SEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)
- SEC Form 4 filed by 5am Partners Vi, Llc
- SEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)
- SEC Form 4: Healy James returned 19,608 shares to the company and sold $85,920 worth of shares (6,000 units at $14.32), closing all direct ownership in the company
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care